Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-09-14
2011-11-29
Kifle, Bruck (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S288000, C544S290000
Reexamination Certificate
active
08067428
ABSTRACT:
Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 3847925 (1974-11-01), Beregi et al.
patent: 5475025 (1995-12-01), Tjoeng et al.
patent: 6413724 (2002-07-01), Gordeev et al.
patent: 845 042 (1952-07-01), None
patent: 08-081442 (1996-03-01), None
patent: 10-502630 (1998-03-01), None
patent: 10-195323 (1998-07-01), None
patent: 2000-204081 (2000-07-01), None
patent: 2003-522177 (2003-07-01), None
patent: WO 94/19341 (1994-09-01), None
patent: WO 94/21602 (1994-09-01), None
patent: WO 96/02508 (1996-02-01), None
patent: WO 99/36425 (1999-07-01), None
patent: WO 01/57037 (2001-08-01), None
Hatzelmann, A., “Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005{(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid} and structurally related compounds,”Biochemical Pharmacology, 1993, vol. 45, No. 1, pp. 101-111.
Holland,Journal of Organic Chemistry, 1961, vol. 26, pp. 1662-1665.
Lacan, F., “Synthesis, structural characterization and thromboxane A2 receptor antagonistic activity of 3-substiuted 2-[(aryslulfonyl) imino]-2, 3-dihydrothiaozyl derivatives,”European Journal of Medicinal Chemistry, 1999, vol. 34, No. 4, pp. 311-328.
Plotnikova, et al., “Arenesulfonamides, LXXX. Aroylarenesulfonamides”, Database CA Online Chemical Abstracts Service, Columbus, OH, US, retrieved from STN Database Accession No. 82 139564 XP002215531, abstract &Vopr. Khim. Khim. Tekhnol. (1974), 33, 20-5.
Stack, D. “Electron Withdrawing and Electron Donating Groups”, 2010, (http://myweb.unomaha.edu/-dstack/2250/Problems/EWG—EDG.doc) 4 pp.
Vippagunta, S.R. et al., “Crystalline solids,”Advanced Drug Delivery Reviews, 2001, vol. 48, pp. 3-26.
Huang Wolin
Jantzen Hans-Michael
Kane-McGuire Kim A.
Marlowe Charles K.
Scarborough Robert M.
Kifle Bruck
Kilpatrick Townsend and Stockton LLP
Portola Pharmaceuticals Inc.
LandOfFree
Platelet ADP receptor inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Platelet ADP receptor inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platelet ADP receptor inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4310193